A new review synthesizes immune pathways and immunotherapy strategies in amyotrophic lateral sclerosis, mapping neuroinflammatory mechanisms that may be tractable for treatment development. Published in Discover Immunity, the article outlines how immune signaling intersects with ALS progression and highlights emerging cellular and immunotherapeutic approaches. The review focuses on the role of neuroinflammation and immune pathway activation in ALS biology, providing a structured view of candidate targets and therapeutic modalities being explored in preclinical and early clinical contexts. For companies building ALS pipelines, the piece provides a consolidated reference point for where the field is converging—especially around immune pathway modulation rather than neuron-centric approaches alone. While a review cannot validate clinical benefit, it can influence target selection and R&D prioritization by clarifying which immune mechanisms have the strongest mechanistic support.